A new market study on the 2022-2028 Thyroid Disorder Therapy Market with 100+ market data Tables, Pie Chat, and Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry-validated market data. The report incorporates a broad evaluation of different methods like combinations and acquisitions, thing headways, and investigation and enhancements embraced by observable market pioneers to stay at the front line in the overall market.
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/2687
The two main types of thyroid disorders are hypothyroidism and hyperthyroidism. Both can be caused by other diseases that impact the way the thyroid gland works. Thyroid disorders may lead to decreased or elevated levels of metabolic hormones. The major factors that may lead to thyroid disorder are iodine deficiency and autoimmune disease.
Increasing prevalence of thyroid cancer and increasing the demand for therapy is expected to augment the growth of the global thyroid disorder therapy market over the forecast period. For instance, according to the National Cancer Institute, in 2016, around 822,242 people in the U.S. were living with thyroid cancer. While, according to the American Cancer Society, over 52,070 new cases of thyroid cancer were reported in the U.S. in 2019, including 2,170 deaths.
In May 2018, the U.S. Food and Drug Administration (FDA) approved the combination of two targeted drugs, trametinib (Mekinist) and dabrafenib (Tafinlar), to treat two different types of cancer. The first approval covers the use of the two-drug combination in some patients with advanced melanoma. Whereas, the second approval covers a subset of patients with a rare and aggressive form of thyroid cancer called anaplastic thyroid cancer. Moreover, Eisai Co., Ltd. received manufacturing and marketing authorization in Japan for its in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) to treat unresectable thyroid cancer.
Furthermore, technological advances in thyroid disorder therapy are expected to boost growth of the global thyroid disorder therapy market.
By Disease Type:
- Thyroid Cancer
By Drug Class:
- Kinase Inhibitors
By Route of Administration:
By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- North America
- Latin America
- Asia Pacific
- Middle East
High cost associated with thyroid disorder therapy is expected to hinder growth of the global thyroid disorder therapy market. For instance, as per the National Center for Biotechnology Information, in 2013, the aggregate national cost of well-differentiated thyroid cancer (WDTC) care was US$ 1.6 billion.
Buy This Report And Get Quick Access – https://www.coherentmarketinsights.com/insight/buy-now/2687
North America is expected to witness significant growth in the global thyroid disorder therapy market due to the high prevalence of thyroid in the region. For instance, as per the American Thyroid Association (ATA), more than 12% of the US population is expected to have thyroid in their lifetime.
Moreover, Asia Pacific is expected to witness substantial growth in the global thyroid disorder therapy market due increasing cases of thyroid in the region. For instance, as per the Indian Thyroid Society (2018 report), over 42 million people have thyroid disorders.
Major players active in the global thyroid disorder therapy market are Pfizer Inc., Mylan N.V., Merck & Co., Novartis A.G., Sanofi, Lanett company, Inc., AbbVie Inc., GlaxoSmithKline, Aspen, and Abbott laboratories, among others.
Get Sample Report with Latest Covid19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/2687
Table Of Content
Chapter No. 1 Introduction
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. USP & Key Offerings
1.2. Key Benefits for Stakehulders
1.3. Target Audience
1.4. Report Scope
Chapter No. 2 Executive Summary
2.1. Key Findings
2.1.1. Top Investment Pockets
184.108.40.206. Market Attractiveness Analysis, By Type
220.127.116.11. Market Attractiveness Analysis, By End Use
18.104.22.168. Market Attractiveness Analysis, By Region
2.2. Market Snapshot
2.3. Global Thyroid Disorder Therapy Market, 2017 – 2022 (USD Million)
2.4. Insights from Primary Respondents
Chapter No. 3 COVID 19 Impact Analysis
3.1. Impact Assessment of COVID-19 Pandemic, By Region
3.1.1. North America
3.1.3. Asia Pacific
3.1.4. Latin America
3.1.5. The Middle-East and Africa
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027